Deutsche Bank AG Sells 20,181 Shares of Evolent Health, Inc $EVH

Deutsche Bank AG decreased its position in shares of Evolent Health, Inc (NYSE:EVH) by 10.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 165,436 shares of the technology company’s stock after selling 20,181 shares during the period. Deutsche Bank AG owned approximately 0.14% of Evolent Health worth $1,567,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Brighton Jones LLC acquired a new position in shares of Evolent Health during the 4th quarter worth approximately $3,927,000. Raymond James Financial Inc. acquired a new position in shares of Evolent Health during the 4th quarter worth approximately $2,542,000. XTX Topco Ltd grew its position in shares of Evolent Health by 71.6% during the 4th quarter. XTX Topco Ltd now owns 23,321 shares of the technology company’s stock worth $262,000 after purchasing an additional 9,731 shares in the last quarter. Marshall Wace LLP grew its position in shares of Evolent Health by 45.1% during the 4th quarter. Marshall Wace LLP now owns 94,320 shares of the technology company’s stock worth $1,061,000 after purchasing an additional 29,328 shares in the last quarter. Finally, First Trust Advisors LP grew its position in shares of Evolent Health by 401.8% during the 4th quarter. First Trust Advisors LP now owns 151,919 shares of the technology company’s stock worth $1,709,000 after purchasing an additional 121,645 shares in the last quarter.

Wall Street Analyst Weigh In

A number of brokerages recently commented on EVH. UBS Group raised their price target on Evolent Health from $14.00 to $15.00 and gave the stock a “buy” rating in a research report on Friday, May 9th. Truist Financial raised their price target on Evolent Health from $14.00 to $16.00 and gave the stock a “buy” rating in a research report on Thursday, July 17th. Needham & Company LLC restated a “buy” rating and issued a $15.00 price target on shares of Evolent Health in a research report on Tuesday, May 13th. Finally, JMP Securities restated a “market outperform” rating and issued a $13.00 price target on shares of Evolent Health in a research report on Friday, June 20th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $17.93.

Evolent Health Stock Performance

NYSE:EVH opened at $9.5750 on Friday. The stock’s 50-day simple moving average is $10.07 and its 200 day simple moving average is $9.56. The firm has a market capitalization of $1.12 billion, a PE ratio of -5.95 and a beta of 0.82. The company has a quick ratio of 1.01, a current ratio of 1.01 and a debt-to-equity ratio of 0.72. Evolent Health, Inc has a twelve month low of $7.06 and a twelve month high of $33.63.

Evolent Health (NYSE:EVH) last released its quarterly earnings data on Thursday, August 7th. The technology company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.20). The business had revenue of $444.33 million during the quarter, compared to analyst estimates of $459.43 million. Evolent Health had a negative net margin of 5.94% and a positive return on equity of 1.83%. The business’s quarterly revenue was down 31.3% compared to the same quarter last year. During the same period last year, the business earned $0.30 earnings per share. Evolent Health has set its Q3 2025 guidance at EPS. On average, analysts anticipate that Evolent Health, Inc will post 0.08 EPS for the current fiscal year.

Evolent Health Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.